BioSpace News Archive

Business

Moderna Posts Q3 Loss, Takes $1.3B in Write-Downs on COVID-19 Shots

While Moderna’s total revenue for the third quarter beat analyst expectations, the company Thursday reported a loss as demand for its COVID vaccines declined.

November 2, 2023
·
2 min read
·
Tyler Patchen
FDA

Amgen Contests J&J’s Stelara with FDA Approval for Interchangeable Biosimilar

Ahead of the Inflation Reduction Act’s drug price negotiations, the regulator has approved Amgen’s biosimilar challenge to Johnson & Johnson’s Stelara—with an interchangeable designation to boot.

November 2, 2023
·
3 min read
·
Tristan Manalac
FDA

Merck’s Keytruda Plus Chemo Secures FDA Approval for Biliary Tract Cancer

The company’s blockbuster cancer drug continues to snap up FDA approvals, this time in treating biliary tract cancer in combination with cisplatin and gemcitabine. It’s the sixth indication in gastrointestinal cancers.

November 2, 2023
·
2 min read
·
Tyler Patchen
Business

Novo Logs Over 700% Wegovy Sales Growth in Q3, Raises 2023 Outlook

Riding a wave of skyrocketing Wegovy and Ozempic sales, the company on Thursday raised its sales and operating profit outlook for the rest of the year as part of its third-quarter earnings announcement.

November 2, 2023
·
2 min read
·
Tristan Manalac
Business

Lilly’s Mounjaro Beats Q3 Expectations, But Company Cuts Full-Year Profit Guidance

Sales of type 2 diabetes treatment Mounjaro brought in $1.4 billion in the third quarter. However, the company cut its full-year profit guidance due to charges mainly related to recent acquisitions.

November 2, 2023
·
1 min read
·
Kate Goodwin
Drug Development

Study Highlights Standout Clinical Success of Certain Cell and Gene Therapies

A recent report by Tufts Medical Center reveals impressive approval rates for durable cell and gene therapies, but experts urge caution over persistent safety and accessibility concerns.

November 2, 2023
·
5 min read
·
Aayushi Pratap
FDA

Novartis Adds Hidradenitis Suppurativa to Cosentyx’s Label in Challenge to Humira

The Swiss pharma has set up its challenge to AbbVie’s blockbuster immunosuppressive drug Humira with a label expansion for Cosentyx in hidradenitis suppurativa, a painful long-term skin condition.

November 2, 2023
·
2 min read
·
Tristan Manalac
BioMidwest

Genezen Secures $18.5 Million in Growth Equity to Expand Viral Vector Development and Manufacturing Capabilities

Genezen, a leading cell and gene therapy Contract Development and Manufacturing Organization, announced the closing of an $18.5 million follow-on growth equity investment led by Ampersand Capital Partners.

November 2, 2023
·
3 min read
Drug Development

Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients

Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies, announced the closing of a CHF25 million Series C financing led by Pureos Bioventures.

November 2, 2023
·
3 min read
Business

Constructive Bio Strengthens Management Team and Board of Directors with Key Appointments to Accelerate Synthetic Genomics to Innovate Biologic Therapies

Constructive Bio, a biotech that rewrites genomes to create biomolecules that were previously unimaginable, announces the appointment of Dr Paul Wallace as Chief Business Officer, and Rahul K Dhanda as a Non-Executive Director with immediate effect.

November 2, 2023
·
4 min read